Navigation Links
Archimedes Pharma Announces Publication of a Pivotal Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in Pain, the Peer-Reviewed Journal from the International Association for the Study of Pain
Date:10/4/2010

BEDMINSTER, N.J., Oct. 4 /PRNewswire/ -- Archimedes Pharma US Inc. today announced publication of results from a pivotal clinical study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain (BTCP). The article, entitled "A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain," has been published in Pain, the peer-reviewed journal from the International Association for the Study of Pain.  

This randomized, placebo-controlled, double-blind study assessed the efficacy and tolerability of FPNS in cancer patients with breakthrough pain in spite of receiving adequate background opioid therapy.  The full text of the study is available at http://www.jpain.org/.

This study met its primary endpoint in demonstrating a significant difference in summed pain intensity difference 30 minutes after dosing (SPID30; p<0.0001).  In addition, significant benefits in pain intensity were noted at five minutes after dosing and were maintained to the end of the assessment period.  Adverse events in the study were typical of an opioid medication in this population.  The most frequently reported adverse events were vomiting, nausea, disease progression and constipation; the majority of such events were mild to moderate in intensity.

The trial's lead investigator, Dr. Russell Portenoy, chairman of the Department of Pain Medicine at New York's Beth Israel Hospital, said, "Both the prevalence and negative impact of breakthrough cancer pain support the need for new treatments.  A rapid onset formulation has a clear rationale, potentially addressing the well documented mismatch between the time course of most breakthrough pains and the time action relationship of oral drugs."

Jeff Buchalter, President and CEO of Archimedes Pharma, commented, "BTCP, which remains under recognized and inadequately managed, affects up to 95% of all cancer patients.  FPNS' proprietary pectin-based transmucosal delivery system is characterized by reduced time to onset of effect, which helps overcome one limitation associated with treatment by conventional opioids."  

Notes to editors:About Archimedes PharmaArchimedes Pharma is an international specialty pharmaceutical company focused on the oncology, pain, neurology, and critical care sectors. Archimedes Pharma is marketing an expanding portfolio of specialist products to hospital-based prescribers in Europe and has established commercial organizations in the UK, US, France, Germany, Ireland, and Spain.

Archimedes Pharma's portfolio includes an innovative fentanyl nasal spray, PecFent®, approved in Europe for the treatment of breakthrough cancer pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain, and is under review by the US Food and Drug Administration (FDA).

PecFent®

PecFent is an innovative fentanyl citrate nasal spray that has been granted Marketing Authorization by the European Medicines Agency for the treatment of breakthrough cancer pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain.

About Breakthrough Cancer Pain (BTCP)

Breakthrough cancer pain affects up to 95% of all cancer patients with pain and is characterized by sudden, unpredictable episodes of intense pain that occur despite background pain medication. This pain is rapid in onset, usually reaching maximum intensity in five minutes and lasting for 30 to 60 minutes.

For more information, please visit: www.archimedespharma.com.Media contacts:Tiberend Strategic Advisors, Inc. (USA)Tamara Bright/Andrew Mielach +1 212-827-0020 tbright@tiberendstrategicadvisors.com/amielach@tiberendstrategicadvisors.comCitigate Dewe Rogerson (UK and Europe)Chris Gardner/Amber Bielecka, +44 207 638 9571 chris.gardner@citigatedr.co.uk/amber.bielecka@citigatedr.co.uk
'/>"/>

SOURCE Archimedes Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects
2. Archimedes Pharma Receives CHMP Positive Opinion for PecFent(R) for the Treatment of Breakthrough Cancer Pain
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... June 24, 2016  Consumers have taken a ... have placed more emphasis on patient outcomes. ... programs in the pharmaceutical industry have evolved beyond ... pharmaceutical companies are focusing on becoming more patient-oriented ... products and services that improve health. ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
Breaking Medicine News(10 mins):